Here are parts of a press release Onyx, makers of the new drug, carfilzomib, released last night at 6:00 PM:
Emeryville, CA – May 20, 2010 – Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL. Presentations will highlight data from the carfilzomib development program in patients with relapsed/refractory multiple myeloma and solid tumors. Each presentation will include updated data at the annual meeting that will not be available in the online abstracts at www.asco.org.
“We are further encouraged by the growing body of evidence that supports carfilzomib’s potential as a new treatment option for patients with multiple myeloma,” said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx. “We look forward to sharing final data from our Phase 2b 003-A1 pivotal trial that we anticipate will form the basis of an initial New Drug Application (NDA) filing for cafilzomib by year end.”
Onyx researchers will be making five important data presentations at ASCO. These include Results of an Ongoing Open-Label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (MM) and a patient quality of life related study, Neurotoxic and Peripheral Neuropathic Effects in Preclinical and Clinical Studies of Carfilzomib, a Novel Proteasome Inhibitor (PI).
I am hoping to conduct a number of interviews with Onyx researchers at ASCO. Tomorrow I am posting an editorial about my impressions, from a multiple myeloma patient’s perspective, about the emergence of carfilzomib. Feel good and keep smiling! Pat